Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class ASSE: 688505

Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid Tumors

· Issued by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid Tumors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis